Buy or sell Guardant Health stock pre IPO via an EquityZen fund
EquityZen is a marketplace for shares of proven pre IPO tech companies
Guardant Health Stock
Bio-tech company focus on oncology
About Guardant Health Stock
Guardant Health is committed to positively and significantly impacting patient health through technology breakthroughs that pointedly address long-standing unmet needs in oncology. Guardant is backed by Sequoia Capital, led by a seasoned management team comprising thought leaders and successful serial entrepreneurs in next-generation sequencing and rare-cell diagnostics and is closely advised by an oncologist-led medical steering committee from leading cancer centers across North America and abroad.
Investors
8VC
Anduril Industries, Sila Nanotechnologies, Cityblock Health, Blend, project44, Addepar, Illumio, Aspiration, BlueVoyant, Guardant Health
Felicis Ventures
Wish, Scopely, Opendoor, Dollar Shave Club, Gusto, Coalition, Crusoe Energy Systems, Plaid, Guild Education, SoundHound
Formation 8
Wish, Oscar Health, Virgin Hyperloop One, Collective Health, Blend, Illumio, Guardant Health, Bolt Threads, Aviatrix, Ironclad
Khosla Ventures
Instacart, Stripe, DoorDash, Impossible Foods, Palantir Technologies, View, Zenefits, Opendoor, Faire, Oscar Health
Lightspeed Venture Partners
Snap, OYO, AppDynamics, TripActions, Faire, Affirm, Netskope, LivingSocial, Weee!, Blend
Sequoia Capital
Market Kurly, Robinhood, Airbnb, Instacart, Tokopedia, Stripe, DoorDash, Rappi, CoinSwitch Kuber, UiPath
SoftBank Capital
Alibaba, SoFi, Ola, Compass, Snapdeal, Plenty, Guardant Health, BuzzFeed, Fitbit, Lemonade
Temasek Holdings
PharmEasy, Tokopedia, Ola, Magic Leap, DoorDash, Impossible Foods, Wish, Snyk, AvidXchange, SambaNova Systems
T. Rowe Price
One97, Flipkart, WeWork, Cruise, Airbnb, Rivian, Magic Leap, Nuro, Caris Life Sciences, Vroom
Funding History
| April 2013 | $9.2M |
|---|---|
| April 2014 | $32.6M |
| December 2014 | $56.0M |
| December 2015 | $83.9M |
| May 2017 | $334M |
Management
Chief Executive Officer
Helmy Eltoukhy
Chief Financial Officer
Derek Bertocci
Chief Legal Officer
Michael Wiley
Chief Medical Officer
Richard Lanman
COO & President
AmirAli Talasaz
VP of Marketing
Sandra Finley
Head of Sales
Stanley Welle
VP of Bioinformatics
Darya Chudova
Vice President, Pharma Business Development
Daniel Simon
Press
Fairfield Current - Nov, 6 2018
Nasdaq - Nov, 1 2018
Nasdaq Place (press release) - Oct, 31 2018
TechCrunch - Oct, 28 2018
MarketWatch - Sep, 6 2018
GenomeWeb - Jul, 31 2018
Forbes - Jul, 19 2018
- Jul, 12 2018
PR Newswire (press release) - May, 23 2018
PR Newswire (press release) - Apr, 26 2018
Healthcare Trends - Apr, 7 2018
PR Newswire (press release) - Mar, 19 2018
PR Newswire (press release) - Mar, 13 2018
PR Newswire (press release) - Feb, 15 2018
Medgadget (blog) - Feb, 12 2018
Incredible News 24 - Jan, 22 2018
PR Newswire (press release) - Nov, 16 2017
PR Newswire (press release) - Nov, 6 2017
Medgadget (blog) - Oct, 17 2017
Healio - Oct, 5 2017
PR Newswire (press release) - Sep, 26 2017
Financial Times - Sep, 24 2017
GenomeWeb - Jun, 22 2017
GenomeWeb - Jun, 5 2017
PR Newswire (press release) - Jun, 3 2017
GenomeWeb - May, 24 2017
PR Newswire (press release) - May, 18 2017
News-Medical.net - May, 15 2017
EquityZen does not have an affiliation with, formal relationship with, or endorsement from any companies featured above. This profile is based on publicly available information and is intended to be informative in nature.
Some data provided by Crunchbase
EquityZen Recognized As:
